arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA
$41.77 ▼ -0.03 (-0.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
46 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Bullish
auto_awesome

Analytical Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $48.7B
Dividend Yield —
Revenue Growth -1.9% ↘
Op. Margin 16.2% ↗
ROIC 7.1% ↗
FCF / Share $0.21 ↘
Trailing P/E 208.9x
Price / Book 6.1x
FCF Yield 0.5%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

46-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.39B
↓ -1.9% —
Net Income Profit after all expenses
$233.00M
↓ -46.2% —
Operating Margin Operating profit as % of sales
16.2%
↑ +391.3% 62th
FCF / Share Free cash flow per share
$0.21
↓ -35.8% —
Long-Term Debt Long-term obligations
$32.52B
↑ +701.5% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
60
Returns ↑
84
Financial Health ↑
62
Cash Quality ↑
72

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 16 years · 46 quarters